2415574
Project Grant
Overview
Grant Description
SBIR Phase I: Development of rod-shaped drug delivery nanoparticles for in-space manufacturing.
The broader impact of this Small Business Innovation Research (SBIR) Phase I project is its potential to transform the solid tumor cancer treatment market, projected to reach $424.6 billion by 2027.
The project aims to advance the regulatory pathway for space-made medicines by using Janus Base Nanoparticles (JBNPs) as a test case to demonstrate comparability with earth-made versions.
This step is crucial for the commercialization of space-made therapeutics, addressing challenges in drug delivery for solid tumors and advancing oncology biotherapeutics.
Additionally, the project will boost U.S. dominance in the space economy, drive innovation and economic growth in biotech, and enhance the nation’s global competitiveness.
It could lead to advanced, safer therapies for various diseases and contribute to fostering a diverse American STEM (Science, Technology, Engineering, and Mathematics) workforce.
Beyond its technological benefits, this project emphasizes diversity, education, and community outreach, promising broader societal and environmental benefits.
Ultimately, it holds potential for positive impacts on the LEO (Low Earth Orbit) commercial space economy and global healthcare.
This Small Business Innovation Research (SBIR) Phase I project aims to tackle the urgent need for advanced drug delivery systems capable of effectively targeting solid tumors.
Current lipid nanoparticles (LNPs), while widely used, face challenges in penetrating the dense extracellular matrix (ECM) of tumors.
EASCRA’s project focuses on creating a regulatory pathway to commercialize space-made Janus Base Nanoparticles (JBNPs).
These nanoparticles, with their nano-rod morphology and DNA-mimicking chemistry, offer improved tumor penetration, effective treatment, and minimal toxicity.
Additionally, JBNPs maintain drug stability and bioactivity at room temperature, overcoming the cold storage challenges faced by LNPs.
Phase I will advance the regulatory approval pathway, laying the groundwork for Phase II, where in-space manufacturing of JBNPs will be optimized.
This technology has the potential to revolutionize cancer treatment by providing a versatile, more effective drug delivery platform.
The success of this project holds significant implications for future space-made medicines, benefiting both terrestrial and space-based healthcare.
This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the foundation's intellectual merit and broader impacts review criteria.
Subawards are not planned for this award.
The broader impact of this Small Business Innovation Research (SBIR) Phase I project is its potential to transform the solid tumor cancer treatment market, projected to reach $424.6 billion by 2027.
The project aims to advance the regulatory pathway for space-made medicines by using Janus Base Nanoparticles (JBNPs) as a test case to demonstrate comparability with earth-made versions.
This step is crucial for the commercialization of space-made therapeutics, addressing challenges in drug delivery for solid tumors and advancing oncology biotherapeutics.
Additionally, the project will boost U.S. dominance in the space economy, drive innovation and economic growth in biotech, and enhance the nation’s global competitiveness.
It could lead to advanced, safer therapies for various diseases and contribute to fostering a diverse American STEM (Science, Technology, Engineering, and Mathematics) workforce.
Beyond its technological benefits, this project emphasizes diversity, education, and community outreach, promising broader societal and environmental benefits.
Ultimately, it holds potential for positive impacts on the LEO (Low Earth Orbit) commercial space economy and global healthcare.
This Small Business Innovation Research (SBIR) Phase I project aims to tackle the urgent need for advanced drug delivery systems capable of effectively targeting solid tumors.
Current lipid nanoparticles (LNPs), while widely used, face challenges in penetrating the dense extracellular matrix (ECM) of tumors.
EASCRA’s project focuses on creating a regulatory pathway to commercialize space-made Janus Base Nanoparticles (JBNPs).
These nanoparticles, with their nano-rod morphology and DNA-mimicking chemistry, offer improved tumor penetration, effective treatment, and minimal toxicity.
Additionally, JBNPs maintain drug stability and bioactivity at room temperature, overcoming the cold storage challenges faced by LNPs.
Phase I will advance the regulatory approval pathway, laying the groundwork for Phase II, where in-space manufacturing of JBNPs will be optimized.
This technology has the potential to revolutionize cancer treatment by providing a versatile, more effective drug delivery platform.
The success of this project holds significant implications for future space-made medicines, benefiting both terrestrial and space-based healthcare.
This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the foundation's intellectual merit and broader impacts review criteria.
Subawards are not planned for this award.
Awardee
Funding Goals
THE GOAL OF THIS FUNDING OPPORTUNITY, "NSF SMALL BUSINESS INNOVATION RESEARCH (SBIR)/ SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) PROGRAMS PHASE I", IS IDENTIFIED IN THE LINK: HTTPS://WWW.NSF.GOV/PUBLICATIONS/PUB_SUMM.JSP?ODS_KEY=NSF23515
Grant Program (CFDA)
Awarding / Funding Agency
Place of Performance
Pawtucket,
Rhode Island
02860-6122
United States
Geographic Scope
Single Zip Code
Eascra Biotech was awarded
Project Grant 2415574
worth $274,990
from National Science Foundation in December 2024 with work to be completed primarily in Pawtucket Rhode Island United States.
The grant
has a duration of 1 year and
was awarded through assistance program 47.084 NSF Technology, Innovation, and Partnerships.
The Project Grant was awarded through grant opportunity NSF Small Business Innovation Research / Small Business Technology Transfer Phase I Programs.
SBIR Details
Research Type
SBIR Phase I
Title
SBIR Phase I: Development of rod-shaped drug delivery nanoparticles for in-space manufacturing
Abstract
The broader impact of this Small Business Innovation Research (SBIR) Phase I project is its potential to transform the solid tumor cancer treatment market, projected to reach $424.6 billion by 2027. The project aims to advance the regulatory pathway for space-made medicines by using Janus base nanoparticles (JBNps) as a test case to demonstrate comparability with Earth-made versions. This step is crucial for the commercialization of space-made therapeutics, addressing challenges in drug delivery for solid tumors and advancing oncology biotherapeutics. Additionally, the project will boost U.S. dominance in the space economy, drive innovation and economic growth in biotech, and enhance the nation’s global competitiveness. It could lead to advanced, safer therapies for various diseases and contribute to fostering a diverse American STEM (Science, Technology, Engineering, and Mathematics) workforce. Beyond its technological benefits, this project emphasizes diversity, education, and community outreach, promising broader societal and environmental benefits. Ultimately, it holds potential for positive impacts on the LEO (Low Earth Orbit) commercial space economy and global healthcare.
This Small Business Innovation Research (SBIR) Phase I project aims to tackle the urgent need for advanced drug delivery systems capable of effectively targeting solid tumors. Current lipid nanoparticles (LNPs), while widely used, face challenges in penetrating the dense extracellular matrix (ECM) of tumors. Eascra’s project focuses on creating a regulatory pathway to commercialize space-made Janus base nanoparticles (JBNps). These nanoparticles, with their nano-rod morphology and DNA-mimicking chemistry, offer improved tumor penetration, effective treatment, and minimal toxicity. Additionally, JBNps maintain drug stability and bioactivity at room temperature, overcoming the cold storage challenges faced by LNPs. Phase I will advance the regulatory approval pathway, laying the groundwork
Topic Code
SP
Solicitation Number
NSF 23-515
Status
(Ongoing)
Last Modified 12/18/24
Period of Performance
12/15/24
Start Date
11/30/25
End Date
Funding Split
$275.0K
Federal Obligation
$0.0
Non-Federal Obligation
$275.0K
Total Obligated
Activity Timeline
Additional Detail
Award ID FAIN
2415574
SAI Number
None
Award ID URI
SAI EXEMPT
Awardee Classifications
Small Business
Awarding Office
491503 TRANSLATIONAL IMPACTS
Funding Office
491503 TRANSLATIONAL IMPACTS
Awardee UEI
NDU4YKLLPTQ1
Awardee CAGE
99B88
Performance District
RI-01
Senators
Sheldon Whitehouse
John Reed
John Reed
Modified: 12/18/24